PetVivo Holdings, Inc. Achieves National Distribution of Spryng™ to More than 600 Veterinary Clinics in 49 States
December 11 2023 - 8:00AM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"),
an emerging biomedical device company focused on the
commercialization of innovative medical devices and therapeutics
for companion animals, achieved a significant milestone – the sale
of its signature product Spryng™ with OsteoCushion™ Technology to
more than 600 veterinary clinics in 49 states.
"We are incredibly excited about the acceptance
by veterinarians of our life changing product, Spryng with
OsteoCushion Technology, which has been distributed to more than
600 clinics in 49 states," said John Lai, Chief Executive Officer
of PetVivo Holdings, Inc. "The rapid increase in the number of
clinics purchasing Spryng demonstrates an advancement in awareness
of Spryng throughout the veterinary community. This advance was
demonstrated by the increase of veterinarian inquiries and podium
speaker references related to Spryng at the American Association of
Equine Practitioners (“AAEP”) conference over the past three years.
When we first launched Spryng at the AAEP conference in Nashville
three years ago no one knew about the product; last year in San
Antonio veterinarians were informing us that they had heard of
Spryng, but were unaware of veterinarians using the product; a few
weeks ago at the AAEP conference in San Diego veterinarians were
sharing with us that they knew veterinarians using the product and
experiencing beneficial results. Such awareness gives us confidence
that veterinarians are reaching for Spryng as a viable option for
the management of lameness and joint related afflictions, such as
osteoarthritis."
SPRYNG™ with OsteoCushion™ Technology, is an
intra-articular injectable veterinary medical device consisting of
sterilized, extra-cellular matrix microparticles. The
microparticles of Spryng have been found to adsorb onto the joint
synovial lining of animals and subsequently integrate with the
animal’s subsynovial tissue. Such action promotes the restoration
of proper joint mechanics, thereby aiding in the management of
lameness and other joint-related afflictions, such as
osteoarthritis.
“We are also seeing enthusiasm surrounding
Spryng in the veterinary community with veterinarians sending us
videos and images touting the benefits of Spryng,” said Mr. Lai.
“For example, Dr. Tomas Infernuso recently provided a video
demonstrating the injection of Spryng in the contralateral knee of
a dog following a TPLO procedure.”
To view an injection of Spryng performed by Dr.
Infernuso please visit:
https://youtube.com/shorts/OqodTbf01i0?feature=share.
For more information about PetVivo Holdings,
Inc. and its innovative product, Spryng, please contact
info1@petvivo.com or visit https://petvivo.com/ and
https://sprynghealth.com/.
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of twenty patents
protects the Company's biomaterials, products, production processes
and methods of use. The Company’s lead product SPRYNG, a
veterinarian-administered, intraarticular injection for the
treatment of lameness and other joint-related afflictions,
including osteoarthritis, in dogs and horses, is currently
available for commercial sale to veterinarians.
CONTACT:
John Lai, CEO PetVivo Holdings, Inc. Email:
info1@petvivo.com (952) 405-6216
Forward-Looking commercial
Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements are
based on information currently available the Company and its
current plans or expectations and are subject to a number of
uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2023 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Nov 2024 to Dec 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Dec 2023 to Dec 2024